Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Presented at: 2022 Gastrointestinal Cancers Symposium; January 20–22, 2022; San Francisco, California. Abstract 379 - Abou-Alfa, G; Chan, SL; Kudo, M (2022)